Payment overview · 2025
General Payments
$106.78
5 reported records · 3 companies
Healthcare provider profile · identity verified
Michael G Mcinnis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANSFIELD, TX · NPI 1033189956
Verified facts
What the public records show
CMS Open Payments records show Michael G Mcinnis, MD received $106.78 in general payments during 2025 across 5 reported records.
Abbott Laboratories accounted for 68.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.70 | 68.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.85 | 16.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.23 | 15.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.78 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.45 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 126 |
| Losartan Potassium | Losartan Potassium | 314 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 80 |
| Metformin Hcl | Metformin Hcl | 270 | 74 |
| Trazodone Hcl | Trazodone Hcl | 218 | 62 |
| Lisinopril | Lisinopril | 199 | 50 |
| Omeprazole | Omeprazole | 170 | 50 |
| Simvastatin | Simvastatin | 161 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 47 |
| Gabapentin | Gabapentin | 140 | 41 |
| Alprazolam | Alprazolam | 138 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 39 |
| Montelukast Sodium | Montelukast Sodium | 138 | 36 |
| Celecoxib | Celecoxib | 135 | 32 |
| Sertraline Hcl | Sertraline Hcl | 129 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 42 |
| Ozempic | Semaglutide | 100 | 17 |
| Carvedilol | Carvedilol | 99 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 26 |
| Glipizide | Glipizide | 84 | 22 |
| Allopurinol | Allopurinol | 80 | 21 |
| Bupropion Xl | Bupropion Hcl | 80 | 23 |
| Atenolol | Atenolol | 79 | 20 |
| Furosemide | Furosemide | 76 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 13 |
| Glimepiride | Glimepiride | 73 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 12 |
| Tramadol Hcl | Tramadol Hcl | 64 | 14 |
| Jardiance | Empagliflozin | 61 | 12 |
| Clonazepam | Clonazepam | 60 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 15 |
| Potassium Chloride | Potassium Chloride | 56 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 31 |
| Donepezil Hcl | Donepezil Hcl | 54 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Meloxicam | Meloxicam | 51 | 13 |
| Eliquis | Apixaban | 49 | 14 |
| Metformin Hcl Er | Metformin Hcl | 48 | 15 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Valsartan | Valsartan | 47 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 14 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 12 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 26 |
| Nitroglycerin | Nitroglycerin | 32 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 11 |
| Estradiol | Estradiol | 31 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Prednisone | Prednisone | 26 | 22 |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 16 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Ramipril | Ramipril | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.78 · 5 records | Abbott Laboratories | FREESTYLE LIBRE, NURTEC ODT, PROCLAIM, TRELEGY ELLIPTA, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error